Journal of Clinical Oncology
Articles in this Issue
Career destination effects of receipt of the American Society of Clinical Oncology Young Investigator Award.
9022 Background: Successful funding during training has long been recognized as a predictor for a career in academic medic...
A novel regimen of liposomal irinotecan plus capecitabine as total neoadjuvant therapy for locally advanced rectal cancer (LipCap): A phase II trial.
e15640 Background: Clinical data on the participation of liposomal irinotecan in neoadjuvant therapy for locally advanced...
Safety and preliminary efficacy of OH2 combined with BS006 sequential intratumoral injection in patients with advanced solid tumors: An open-label, dose-escalation phase Ib/II study.
2590 Background: The immunosuppressive (“cold”) tumor microenvironment (TME) limits patient response to checkpoint inhibit...
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.
12138 Background: Pembrolizumab 400 mg every 6 weeks (Q6W) was approved based on population pharmacokinetic (pop-PK) model...
Uterine cancer mortality and demographic disparities in the United States in relation to female obesity.
e17616 Background: Uterine Cancer is the sixth most common cause of death in women. The incidence and mortality rates of u...
Immune-related adverse events and associated clinical outcomes in cancer patients treated with immune checkpoint inhibitors: A multicenter real-world study.
e24149 Background: Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment to boost the immune system's ab...
Association of concurrent GLP-1 receptor agonist use with survival outcomes in patients with metastatic colorectal cancer receiving immune checkpoint inhibitors.
3605 Background: Metabolic status and systemic inflammation are increasingly recognized as important modifiers of immune c...
Impact of treatment sequence of immunotherapy and stereotactic radiotherapy on survival in non–small cell lung cancer patients with brain and bone metastases: An NCDB data analysis.
e20119 Background: Optimizing the sequence of immunotherapy (IT) and stereotactic radiotherapy (SRT) in metastatic non-sma...
Nanoscale spatial profiling of DLL3, SEZ6, and B7-H3 in small cell lung cancer using a rapid expansion microscopy assay.
e15194 Background: Small cell lung cancer (SCLC) remains an aggressive malignancy with limited therapeutic options. Recent...
The global and regional burden of leukemia from 1990-2023: A systematic analysis for the Global Burden of Disease study 2023.
e18625 Background: Leukemia represents an important component of global hematologic malignancy burden across the age spect...
Radiotherapy in symptomatic metastatic triple-negative breast cancer treated with first-line pembrolizumab and chemotherapy: A multinational real-world study.
e13112 Background: Despite the addition of pembrolizumab to chemotherapy, the prognosis of patients with symptomatic metas...
Enhancing OP-35 classification of potentially avoidable hospital visits after chemotherapy using procedure codes.
e23075 Background: Medicare’s OP-35 quality measure defines potentially avoidable hospital visits within 30 days of outpat...
Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid.
e15184 Background: Quaratusugene ozeplasmid is a gene therapy that delivers a plasmid coding for the TUSC2 tumor suppresso...
ALPACCA: Phase 3 trial of firmonertinib vs investigator’s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006).
TPS8675 Background: Despite advances in treatment of NSCLC with EGFR classical mutations, no universally accepted standard...
Survival differences in advanced gynecological cancers after the development of immune checkpoint inhibitors and targeted therapy: United States SEER-based population study.
e17652 Background: Immune checkpoint inhibitors (ICI) are being used for advanced gynecological cancers (cervix, endometri...
Phase Ib expansion and dose optimization study of CX-5461 in patients with solid tumours enriched for DNA-repair deficiencies.
3091 Background: G-quadruplexes (G4) are guanine-rich DNA/RNA structures that contribute to DNA damage and genomic instabi...
TROP2 as an actionable biomarker for anal cancer.
3519 Background: Chemoimmunotherapy is standard frontline therapy for metastatic anal cancer, with no effective treatment...
Association between the rs72725854(A>T) allele and prostate cancer in males of African ancestry in a US population-based database.
10504 Background: Black males have a 70% excess incidence of and two-fold higher mortality from prostate cancer (PCa) comp...
Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: A systematic review and meta-analysis.
542 Background: Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) is a cornerstone o...
Sacituzumab govitecan in combination with capecitabine for the treatment of advanced gastrointestinal cancers after progression on standard therapy.
TPS4271 Background: Gastrointestinal (GI) malignancies are associated with poor survival and novel therapies are urgently...
Neoadjuvant fractionated stereotactic radiotherapy followed by surgical resection for brain metastases: A multicenter, single arm phase II trial (NEO-TACTICS).
2003 Background: Surgical resection followed by adjuvant radiotherapy for brain metastases (BM) is associated with unresol...
Updated results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial.
4054 Background: While PD-1 inhibitors plus chemotherapy have become standard first-line therapy for advanced HER2-negativ...
Microbiota prognostic signature in colon cancer.
e15637 Background: Stage II and III colon cancer (CC) poses a significant challenge due to rising global incidence and mor...
REVO-U: A next-generation, gene-editing–free universal CAR-T platform to enable ultra–high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL.
7013 Background: We previously invented autologous CAR-T product ciltacabtagene autoleucel (Carvykti) for multiple myeloma...
Persistent and divergent cervical cancer burden in Sub-Saharan Africa, 1990–2023.
e22588 Background: Cervical cancer is among the most preventable malignancies, yet sub-Saharan Africa (SSA) bears the high...